Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
RVNC Revance Therapeutics, Inc. daily Stock Chart
RVNC [NASD]
Revance Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-3.79 Insider Own1.20% Shs Outstand50.32M Perf Week13.97%
Market Cap1.39B Forward P/E- EPS next Y-3.92 Insider Trans0.00% Shs Float49.09M Perf Month24.80%
Income-154.70M PEG- EPS next Q-0.98 Inst Own92.50% Short Float11.03% Perf Quarter73.02%
Sales0.80M P/S1734.78 EPS this Y1.60% Inst Trans8.85% Short Ratio6.04 Perf Half Y146.69%
Book/sh3.49 P/B7.90 EPS next Y-7.70% ROA-55.60% Target Price35.80 Perf Year53.48%
Cash/sh4.15 P/C6.64 EPS next 5Y11.60% ROE-87.60% 52W Range9.88 - 27.06 Perf YTD69.93%
Dividend- P/FCF- EPS past 5Y1.30% ROI-100.00% 52W High1.92% Beta1.23
Dividend %- Quick Ratio6.50 Sales past 5Y43.30% Gross Margin- 52W Low179.15% ATR1.25
Employees170 Current Ratio6.50 Sales Q/Q-98.10% Oper. Margin- RSI (14)73.14 Volatility5.42% 4.48%
OptionableYes Debt/Eq0.00 EPS Q/Q-5.60% Profit Margin- Rel Volume1.00 Prev Close26.68
ShortableYes LT Debt/Eq0.00 EarningsFeb 24 AMC Payout- Avg Volume896.91K Price27.58
Recom1.80 SMA2014.73% SMA5036.96% SMA20086.13% Volume890,435 Change3.37%
Dec-02-19Initiated Goldman Buy
Oct-30-19Upgrade Wells Fargo Market Perform → Outperform $20
Jun-11-19Initiated Barclays Overweight $28
Feb-15-19Initiated Wells Fargo Market Perform
Feb-14-19Initiated H.C. Wainwright Buy $25
Jan-29-19Initiated Stifel Buy $50
Nov-16-18Upgrade Guggenheim Neutral → Buy
Sep-17-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Apr-20-18Reiterated Mizuho Buy $54 → $48
Mar-27-18Initiated Needham Buy $42
Mar-05-18Initiated Goldman Buy $60
Jan-09-18Downgrade Guggenheim Buy → Neutral
Dec-06-17Reiterated Mizuho Buy $37 → $54
Dec-06-17Initiated Guggenheim Buy $42
Nov-27-17Initiated Barclays Overweight $31
Nov-17-17Initiated Mizuho Buy $37
Aug-22-17Initiated JMP Securities Mkt Outperform $34
Nov-29-16Initiated Aegis Capital Buy $28
Jun-14-16Reiterated SunTrust Buy $46 → $22
Jun-14-16Reiterated Piper Jaffray Overweight $54 → $35
Feb-14-20 08:00AM  Revance to Release Fourth Quarter and Full Year 2019 Financial Results on Monday, February 24, 2020 Business Wire
Feb-12-20 06:55AM  Revance Announces Pricing of $250 Million of Convertible Senior Notes Due 2027 Business Wire
Feb-10-20 04:08PM  Revance Announces Proposed Private Offering of $200 Million of Convertible Senior Notes Due 2027 Business Wire
Feb-07-20 07:32AM  The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns Benzinga
Feb-06-20 08:00AM  Revance Announces U.S. FDA Acceptance of Biologics License Application (BLA) for DAXI to Treat Glabellar (Frown) Lines Business Wire
Jan-21-20 05:32AM  Will Revance Therapeutics Continue to Surge Higher? Zacks
Jan-19-20 09:13AM  3 Strong Buy Biotech Stocks That Can Inject a Healthy Dose of Upside TipRanks
Jan-10-20 10:11AM  Did Changing Sentiment Drive Revance Therapeutics's (NASDAQ:RVNC) Share Price Down By 25%? Simply Wall St. +18.29%
08:05AM  Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA Business Wire
Jan-09-20 04:05PM  Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference Business Wire
08:05AM  Revance Provides Corporate Update and Anticipated Milestones for 2020 Business Wire
Dec-20-19 05:35PM  Did Hedge Funds Drop The Ball On Revance Therapeutics Inc (RVNC) ? Insider Monkey
Dec-05-19 08:00AM  Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology Business Wire
Dec-04-19 07:41AM  Revance Announces Pricing of Public Offering of Common Stock Business Wire -17.57%
07:06AM  The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug Benzinga
Dec-03-19 04:01PM  Revance Announces Proposed Public Offering of Common Stock Business Wire
Dec-02-19 08:00AM  Revance Promotes Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics Business Wire +11.87%
Nov-25-19 08:00AM  Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines Business Wire
Nov-24-19 04:19PM  The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More Benzinga
Nov-15-19 04:29PM  Edited Transcript of RVNC earnings conference call or presentation 4-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 04:05PM  Revance to Participate in the Stifel 2019 Healthcare Conference Business Wire
Nov-06-19 04:05PM  Revance to Participate in the Credit Suisse 28th Annual Healthcare Conference Business Wire
Nov-05-19 06:43AM  3 Hot Biotech Stocks With 100% Street Support TipRanks
Nov-04-19 04:10PM  Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update Business Wire
04:05PM  Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia Business Wire
08:00AM  Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery Business Wire
Oct-30-19 01:09PM  Wells Fargo Turns Bullish On Revance Therapeutics After Meeting With Management Benzinga
09:46AM  Is Revance Therapeutics Inc (RVNC) A Good Stock To Buy? Insider Monkey
Oct-28-19 04:05PM  Revance to Release Third Quarter 2019 Financial Results on Monday, November 4, 2019 Business Wire
Oct-23-19 08:00AM  Revance to Present Clinical Data Highlighting the Efficacy and Safety of DAXI at the ASDS 2019 Annual Meeting Business Wire
Oct-18-19 10:23AM  These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year American City Business Journals
Oct-15-19 05:04PM  Allergan (AGN) Shareholders Approve Acquisition by AbbVie Zacks
04:55PM  'Misjudgment' in employee matter leads to departure of East Bay drug maker CEO American City Business Journals
Oct-14-19 08:00AM  Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne Business Wire +15.11%
Oct-08-19 03:30PM  We're Hopeful That Revance Therapeutics (NASDAQ:RVNC) Will Use Its Cash Wisely Simply Wall St.
Oct-02-19 04:05PM  Revance Earns Great Place to Work® Certification for Second Year Business Wire
Sep-25-19 04:05PM  Revance to Participate in the 2019 Cantor Global Healthcare Conference Business Wire
Sep-04-19 04:05PM  Revance to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference Business Wire
Aug-28-19 04:05PM  Revance to Participate in the Wells Fargo 14th Annual Healthcare Conference Business Wire
Aug-23-19 12:06PM  Does Revance Therapeutics, Inc.'s (NASDAQ:RVNC) CEO Pay Compare Well With Peers? Simply Wall St.
Aug-12-19 09:10PM  Edited Transcript of RVNC earnings conference call or presentation 5-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-06-19 08:24PM  Revance Therapeutics (RVNC) Q2 2019 Earnings Call Transcript Motley Fool
Aug-05-19 04:05PM  Revance Reports Second Quarter 2019 Financial Results, Provides Corporate Update Business Wire
02:30PM  Revance Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Jul-29-19 04:05PM  Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019 Business Wire
Jul-25-19 10:33AM  Will Revance Therapeutics (RVNC) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-17-19 08:00AM  Revance Adds Life Sciences Audit Executive Chris Nolet to Board of Directors Business Wire
Jul-09-19 10:50AM  Did Changing Sentiment Drive Revance Therapeutics's (NASDAQ:RVNC) Share Price Down A Worrying 59%? Simply Wall St.
Jul-08-19 09:41AM  AbbVie (ABBV) Shares Down So Far This Year: Here's Why Zacks
Jun-26-19 02:06PM  Is Revance Therapeutics Inc (RVNC) A Good Stock To Buy? Insider Monkey
09:13AM  Here's Why Nobody's Happy About This $63 Billion Buyout Motley Fool
08:42AM  Revance Therapeutics (RVNC) Jumps: Stock Rises 5.2% Zacks
Jun-06-19 08:05AM  Revance Adds Iconic Brand Builder Jill Beraud to Board of Directors Business Wire
Jun-04-19 04:05PM  Revance to Participate in the Goldman Sachs 40th Annual Global Healthcare Conference Business Wire
May-22-19 01:33AM  Edited Transcript of RVNC earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-14-19 04:05PM  Revance to Participate in the RBC Capital Markets 2019 Healthcare Conference Business Wire
May-09-19 10:23AM  Revance Therapeutics (RVNC) Q1 2019 Earnings Call Transcript Motley Fool
May-08-19 04:05PM  Revance Reports First Quarter 2019 Financial Results and Provides Corporate Update Business Wire
May-07-19 12:51PM  Is Revance Therapeutics Inc (RVNC) A Good Stock To Buy? Insider Monkey
May-01-19 02:21PM  A Spotlight On Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Fundamentals Simply Wall St.
10:32AM  Will Revance Therapeutics (RVNC) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-24-19 04:05PM  Revance to Release First Quarter 2019 Financial Results on Wednesday, May 8, 2019 Business Wire
Apr-09-19 08:00AM  Revance Appoints Former Allergan Marketing Veteran Taryn Conway as Vice President of Marketing Business Wire
Apr-08-19 04:05PM  SAKURA 3 Trial Results Presented on Podium at Worlds Largest Medical Aesthetic Conference Business Wire
Apr-04-19 05:46PM  Maker of Botox alternative turns toxin on crippling muscle disorder American City Business Journals
Apr-02-19 04:05PM  Revance to Participate in the Needham Healthcare Conference Business Wire
Apr-01-19 01:48PM  Does Revance Therapeutics, Inc. (NASDAQ:RVNC) Have A Volatile Share Price? Simply Wall St.
07:15AM  New Research: Key Drivers of Growth for Fresh Del Monte Produce, Baker Hughes, a GE company, HollyFrontier, Glaukos, HCI Group, and Revance Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-05-19 04:05PM  Revance to Participate in Upcoming Investor Conferences Business Wire
Mar-01-19 10:18AM  Edited Transcript of RVNC earnings conference call or presentation 26-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
05:48AM  Revance Therapeutics Inc (RVNC) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Feb-28-19 08:08AM  Need To Know: Revance Therapeutics, Inc. (NASDAQ:RVNC) Insiders Have Been Buying Shares Simply Wall St.
Feb-26-19 08:00PM  Revance Therapeutics Inc (RVNC) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:05PM  Revance Releases Fourth Quarter and Full Year 2018 Results Business Wire
Feb-12-19 04:05PM  Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019 Business Wire
Feb-11-19 09:00AM  CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors GlobeNewswire
Feb-05-19 08:15AM  Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines Zacks
Jan-28-19 07:23AM  What Kind Of Shareholders Own Revance Therapeutics, Inc. (NASDAQ:RVNC)? Simply Wall St.
Jan-25-19 07:30AM  Investor Expectations to Drive Momentum within International Paper, Gray Television, Nielsen Holdings Plc, e.l.f. Beauty, NIC, and Revance Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Jan-22-19 04:05PM  Revance Announces Closing of Public Offering of Common Stock Business Wire
Jan-17-19 06:50AM  Revance Announces Pricing of Public Offering of Common Stock Business Wire
Jan-16-19 08:24AM  The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen Benzinga -10.28%
Jan-15-19 04:17PM  Revance Announces Proposed Public Offering of Common Stock Business Wire
08:05AM  Revance Announces Ground-Breaking Data Presentations at Leading International Neurotoxin Conference Business Wire
Jan-07-19 08:05AM  Revance Highlights Recent Regulatory Progress and Provides Anticipated 2019 Milestones Business Wire
Dec-05-18 06:50AM  Today's Research Reports on Trending Tickers: Novelion Therapeutics and Revance Therapeutics ACCESSWIRE
Dec-04-18 02:08PM  Revance Therapeutics reaches licensing agreement with Fosun Pharmaceutical over botox formulation RT002 MarketWatch +19.47%
11:12AM  Revance Therapeutics' Botox rival succeeds in late-stage trial Reuters
08:27AM  Revance Therapeutics' frown lines treatment succeeds in late-stage trial Reuters
08:06AM  Revance Announces China Market License Agreement with Fosun Pharma for RT002 Business Wire
08:05AM  Revances RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program Business Wire
Nov-27-18 07:40AM  Market Trends Toward New Normal in Palatin Technologies, Revance Therapeutics, Geo Group, QUANTENNA COMMS, The Navigators Group, and INVESCO MORTGAGE CAPITAL INC Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-20-18 04:05PM  Revance to Participate in Upcoming Investor Conferences Business Wire
Nov-16-18 03:48PM  Edited Transcript of RVNC earnings conference call or presentation 1-Nov-18 8:30pm GMT Thomson Reuters StreetEvents
Nov-15-18 12:20PM  Why Revance Therapeutics Incs (NASDAQ:RVNC) CEO Pay Matters To You Simply Wall St.
Nov-07-18 04:05PM  Revance to Participate in the Credit Suisse Healthcare Conference Business Wire
Nov-01-18 04:05PM  Revance Releases Third Quarter 2018 Results Business Wire +5.70%
Oct-18-18 04:05PM  Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018 Business Wire
Oct-11-18 09:00AM  Investor Expectations to Drive Momentum within Materion, Iridium Communications, Natural Health Trends, Revance Therapeutics, Baxter International, and Alexion Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
08:30AM  Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer Business Wire
Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine. It is also developing DAXI for forehead lines and lateral canthal lines; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. Revance Therapeutics, Inc. has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Browne L DanielCEO and PresidentMar 18Sale15.5111,613180,068151,193Mar 19 09:01 PM
Allouche CyrilPrincipal Accounting OfficerMar 18Sale15.484987,7096,400Mar 19 08:58 PM
Joshi AbhayChief Operating OfficerMar 14Option Exercise4.206662,79790,443Mar 18 08:34 PM
open in yahoo | open in reuters | open in google